(52), recently demonstrated ORC6 as prognostic for overall survival, disease-specific survival, disease-free interval, and progress-free interval in several cancers including the prostate, and that ORC6 may promote immunosuppression in a wide array of cancer. This evidence concerns the gene ORC6 and cancer.